Gotowe bibliografie tematyczne / Migraine

Gotowa bibliografia na temat „Migraine”

Autor: Grafiati
Data publikacji: 4 czerwca 2021
Data aktualizacji: 29 lipca 2024

Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych

Wybierz rodzaj źródła:

Spis treści

Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Migraine”.

Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.

Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.

Artykuły w czasopismach na temat "Migraine"

1

Cuciureanu, Dan Iulian, Cătălina Elena Bistriceanu, Georgiana-Anca Vulpoi, Tudor Cuciureanu, Florina Antochi i Adina-Maria Roceanu. "Migraine Comorbidities". Life 14, nr 1 (2.01.2024): 74. http://dx.doi.org/10.3390/life14010074.

Pełny tekst źródła
Streszczenie:
Novel knowledge about the interrelationships and reciprocal effects of migraine and epilepsy, migraine and mood disorders, or migraine and irritable bowel syndrome has emerged in recent decades. Over time, comorbid pathologies associated with migraine that share common physiopathological mechanisms were studied. Among these studied pathologies is epilepsy, a disorder with common ion channel dysfunctions as well as dysfunctions in glutamatergic transmission. A high degree of neuronal excitement and ion channel abnormalities are associated with epilepsy and migraine and antiepileptic drugs are useful in treating both disorders. The coexistence of epilepsy and migraine may occur independently in the same individual or the two may be causally connected. The relationship between cortical spreading depression (CSD) and epileptic foci has been suggested by basic and clinical neuroscience research. The most relevant psychiatric comorbidities associated with migraine are anxiety and mood disorders, which influence its clinical course, treatment response, and clinical outcome. The association between migraine and major depressive disorder can be explained by a robust molecular genetic background. In addition to its role as a potent vasodilator, CGRP is also involved in the transmission of nociception, a phenomenon inevitably linked with the stress and anxiety caused by frequent migraine attacks. Another aspect is the role of gut microbiome in migraine’s pathology and the gut–brain axis involvement. Irritable bowel syndrome patients are more likely to suffer migraines, according to other studies. There is no precise explanation for how the gut microbiota contributes to neurological disorders in general and migraines in particular. This study aims to show that migraines and comorbid conditions, such as epilepsy, microbiota, or mood disorders, can be connected from the bench to the bedside. It is likely that these comorbid migraine conditions with common pathophysiological mechanisms will have a significant impact on best treatment choices and may provide clues for future treatment options.
Style APA, Harvard, Vancouver, ISO itp.
2

Yamanaka, Gaku, Soken Go, Shinichiro Morichi, Mika Takeshita, Natsumi Morishita, Shinji Suzuki, Takamatsu Tomoko i in. "Clinical Features and Burden Scores in Japanese Pediatric Migraines With Brainstem Aura, Hemiplegic Migraine, and Retinal Migraine". Journal of Child Neurology 35, nr 10 (1.06.2020): 667–73. http://dx.doi.org/10.1177/0883073820927840.

Pełny tekst źródła
Streszczenie:
Background: Migraines are a broad spectrum of disorders classified by the type of aura with some requiring attentive treatment. Vasoconstrictors, including triptans, should be avoided in the acute phase of migraines with brainstem aura, in hemiplegic migraine, and in retinal migraine. This study investigated the characteristics and burden of these migraines. Methods: Medical charts of 278 Japanese pediatric patients with migraines were retrospectively reviewed. Migraine burden of migraines with brainstem aura, hemiplegic migraines, and retinal migraine was assessed using the Headache Impact Test-6™ (HIT-6) and the Pediatric Migraine Disability Assessment scale (PedMIDAS). Results: Of 278 patients screened, 12 (4.3%) patients with migraines with brainstem aura (n = 5), hemiplegic migraines (n = 2), and retinal migraine (n = 5) were enrolled in the study. All patients had migraine with/without typical aura, whereas some patients had coexisting migraine with another type of headache (chronic tension-type headache in 3 patients, and 1 each with frequent episodic tension-type headache, headache owing to medication overuse, and chronic migraine). Migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients with coexisting headaches had higher HIT-6 or PedMIDAS scores, whereas migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients without coexisting headache did not show high HIT-6 or PedMIDAS scores. Conclusion: All migraines with brainstem aura, hemiplegic migraines, and retinal migraine patients experienced migraine with or without typical aura, and some patients having other coexisting headaches also had high PedMIDAS and HIT-6 scores. PedMIDAS and HIT-6 should not be considered diagnostic indicators of migraines with brainstem aura, hemiplegic migraines, or retinal migraine. In clinical practice for headaches in children, careful history taking and proactive assessment of the aura are needed for accurate diagnosis of migraines with brainstem aura, hemiplegic migraines, and retinal migraine.
Style APA, Harvard, Vancouver, ISO itp.
3

Simic, Svetlana, Petar Slankamenac, Milan Cvijanovic, Sofija Banic-Horvat, Zita Jovin i Miroslav Ilin. "Menstrual migraine". Medical review 60, nr 9-10 (2007): 449–52. http://dx.doi.org/10.2298/mpns0710449s.

Pełny tekst źródła
Streszczenie:
Introduction. The prevalence of migraine in childhood and adolescence has not changed to a great extent, but it increases in adolescence, especially in female adolescents. Menstrual migraine ? definition. There are two types of menstrual migraine: true menstrual migraine and menstrual related migraine. True menstrual migraine occurs predominantly around menstruation, whereas menstrual related migraine occurs during menstruation, but also at other times during the month. Causes. Exaggerated or abnormal neurotransmitter responses to normal cyclic changes in the ovarian hormones are probably the basic cause of menstrual migraines. The fall in estrogen levels during menstrual cycle is trigger for the menstrual migraine. Symptoms. Menstrual migraine has the same symptoms as other types of migraine, but the pain is stronger, IT lasts longer, AND IT IS more frequent than other types of migraines. Diagnosis. In order to make a diagnosis, women are asked to keep a headache diary for three months. If the migraine headache is severe and occurs regularly between two days before and three days after the start of menstrual bleeding, it is true menstrual migraine. Therapy. Menstrual migraines are more difficult to treat than other types of migraines. Treatment principles for menstrual migraine are the same as for migraines in general, with certain particularities. Conclusion. Hormonally associated migraine is a specific clinical entity. It is important to diagnose the type of migraine, considering the fact that a decline in estrogen level at the end of menstrual cycle triggers migraine, so it can be treated by low levels of estrogen. .
Style APA, Harvard, Vancouver, ISO itp.
4

Susanti, Restu, i Syamel Muhammad. "Menstrual Migraine : How Hormones Impact Migraine". Journal Obgin Emas 5, nr 1 (18.01.2021): 9–17. http://dx.doi.org/10.25077/aoj.5.1.9-17.2021.

Pełny tekst źródła
Streszczenie:
Menstrual Migraine is divided into 2 subtypes: Menstrually Related Migraine (MRM) and Pure Menstrual Migraines (PMM). In PMM symptoms do not occur outside the menstrual cycle while MRM, symptoms can occur at other times apart from the menstrual cycle. The occurrence of menstrual migraines is related to the female hormones cycle in the form of the decrease in estrogen levels which usually occurs a week before the onset of menstruation. The mechanism is unclear, but it is thought that a decrease in estrogen levels can trigger decrease in serotonin levels, causing cranial vasodilation and sensitization of the trigeminal nerve. Keywords: menstrual migraine, hormones
Style APA, Harvard, Vancouver, ISO itp.
5

Sun, Juan. "Migraines in medical students from Inner Mongolia University". Pacific International Journal 5, nr 3 (1.10.2022): 65–77. http://dx.doi.org/10.55014/pij.v5i3.201.

Pełny tekst źródła
Streszczenie:
Aims: This study aimed to evaluate the prevalence of migraines and related factors. Methods: The survey employed was a self-administered questionnaire regarding various migraine symptoms and related factors administered to medical students attending Inner Mongolia Medical College in China. We calculate migraine prevalence and evaluate migraine-related factors. Migraine prevalence based on related factors and according to gender were compared using χ2 tests. The proportion of other symptoms related to migraines was also calculated. Results: 17.2% of surveyed students had experienced migraines. The migraines prevalence among students who used the computer for over three hours was nearly 1.5 times higher than for those who used it for less than one hour. Of those students who used a computer for more than 3 hours, migraine prevalence among female students was approximately 1.5 times greater than for males. The migraine prevalence among students with poor sleep was nearly two times higher than among those with good sleep. The migraine prevalence among students with anxiety was approximately 2.5 times higher relative to those who experienced no anxiety. The most common symptom complaint associated with migraines (>97%) included limited ability to study and restricted daily activities. Conclusions: Although the migraine prevalence in our study was moderate, it led to serious limitations in students’ study time and daily activities. In addition to measures to relieve anxiety and improve sleep quality, stricter control of computer use will be necessary, especially in female. Taken together, our study provides better insight regarding medical students’ migraine-related problems.
Style APA, Harvard, Vancouver, ISO itp.
6

Kumaat, Matthew A., Junita M. Pertiwi i Arthur H. P. Mawuntu. "Hubungan antara Migrain dan Kafein". e-CliniC 9, nr 2 (16.03.2021): 334. http://dx.doi.org/10.35790/ecl.v9i2.32864.

Pełny tekst źródła
Streszczenie:
Abstract: Migraine is one of the primary headaches that often causes moderate to severe disability. One of the most commonly consumed psychoactive substances associated with migraine is caffeine. This study was aimed to evaluate the relationship between migraine and caffeine thoroughly based on various studies. This was a literature review study using databases of Pubmed/Medline, Cochrane, Wiley Online Library, Science Direct, Google Scholar, and Garuda. The eligibility criteria for this study were observational research articles or clinical trials, written in Indonesian or English, published in the last five years, and their fulltexts could be accessed. The results obtained 10 articles. Almost all of them showed that caffeine could cause migraine whether after caffeine consumption (non-absent group) or no consumption of caffeine (absent group). The association of caffeine with migraine was more significant than with tension headaches. Besides being a trigger factor of migraine, caffeine cpuld also act as a migraine therapy. In conclusion, there is a close association between migraine and caffeine. Migraine tends to be triggered than to be reduced by caffeine.Keywords: caffeine, migraine Abstrak: Migrain merupakan salah satu jenis nyeri kepala primer yang sering menyebabkan disabilitas sedang dan berat. Salah satu zat psikoaktif yang umum dikonsumsi dan berhubungan dengan migrain yaitu kafein. Penelitian ini bertujuan untuk menelaah hubungan migrain dan kafein lebih mendalam berdasarkan berbagai penelitian. Jenis penelitian ialah literature review menggunakan database dari Pubmed/Medline, Cochrane, Wiley Online Library, Science Direct, Google Scholar, dan Garuda. Kriteria kelayakan artikel penelitian ialah artikel penelitian observasional atau uji klinis, ditulis dalam Bahasa Indonesia atau Inggris, terbit dalam lima tahun terakhir, dan naskah lengkap artikel dapat diakses secara lengkap. Hasil penelitian mendapatkan 10 artikel penelitian. Hampir semua penelitian memperlihatkan bahwa kafein dapat menyebabkan migrain baik setelah kafein dikonsumsi (kelompok nonabsen) maupun saat kafein sudah tidak dikonsumsi (kelompok absen). Hubungan kafein dengan migrain lebih kuat dibandingkan dengan nyeri kepala tipe tegang. Selain menjadi factor pencetus, kafein juga dapat berperan sebagai terapi migrain. Simpulan penelitian ini ialah terdapat hubungan erat antara migrain dan kafein. Migrain cenderung lebih sering dicetuskan oleh kafein dibandingkan diringankan oleh kafein.Kata kunci: kafein, migrain
Style APA, Harvard, Vancouver, ISO itp.
7

Reuter, U., MS Del Rio, H.-C. Diener, G. Allais, B. Davies, A. Gendolla, J. Pfeil, S. Schwalen, B. Schäuble i J. van Oene. "Migraines with and without aura and their response to preventive therapy with topiramate". Cephalalgia 30, nr 5 (1.10.2009): 543–51. http://dx.doi.org/10.1111/j.1468-2982.2009.01999.x.

Pełny tekst źródła
Streszczenie:
Data from the Prolonged Migraine Prevention (PROMPT) with Topiramate trial were evaluated post hoc to determine whether topiramate could prevent migraine auras, and whether its efficacy in preventing migraine headaches was similar in patients with (MA; n = 269) and without (MoA; n = 542) aura. Migraines and auras were recorded during prospective baseline, 6-month open-label (OL) topiramate and 6-month double-blind (DB), placebo-controlled phases. In the last 28 OL days, migraines without aura and migraine auras decreased by 43.1% and 54.1%, respectively, in MA patients. MoA patients experienced a 44.3% reduction in migraines. In the DB phase, increases in migraines with placebo vs. topiramate were similar to the full study, but were generally not statistically significant, probably due to lack of power in the subgroup analysis. Similarly, there were no statistically significant changes in number of auras between groups. Thus, topiramate appears to reduce migraine auras in parallel with headache reductions, which are similar in patients with and without aura.
Style APA, Harvard, Vancouver, ISO itp.
8

Fu, Xianguo, Jing Yang, Xiaoyang Wu, Qifang Lin, Yuli Zeng, Qiaoqing Xia, Luoyuan Cao, Baoying Huang i Genbin Huang. "Association between PRDM16, MEF2D, TRPM8, LRP1 gene polymorphisms and migraine susceptibility in the She ethnic population in China". Clinical and Investigative Medicine 42, nr 1 (23.03.2019): E21—E30. http://dx.doi.org/10.25011/cim.v42i1.32389.

Pełny tekst źródła
Streszczenie:
Background: The prevalence of migraines in the She population, a minority in China, is significantly higher than that in Han Chinese and other Asian populations. Two single nucleotide polymorphisms (SNPs) have been found to be associated with migraine susceptibility in the She population. Purpose: This study investigated four SNPs, identified in genome-wide association studies, within migraine-susceptible loci in Han Chinese for their association with migraine susceptibility in the She population. Methods: Two-hundred unrelated migraine patients and 200 healthy controls were recruited. The SNPs examined included rs2651899 (PRDM16 ), rs2274316 (MEF2D ), rs7577262 (TRPM8) and rs11172113 (LRP1). Genotyping of the SNPs was performed by allele-specific polymerase chain reaction and direct sequencing. Results: No significant differences between the participants with migraines and controls (participants without migraines) were demonstrated in genotypes, alleles and allele carriage frequencies for the four SNPs. A subgroup analysis found that migraine with aura had a lower frequency of C allele positivity in rs2651899 than in healthy controls (59.6% vs. 74.5%, respectively; P < 0.034). Univariate analyses indicated that no genotype of the four SNPs had a significant association with migraines. Males had a lower risk of migraines, and advanced age was a significant risk factor for migraines in females. Conclusion: The SNPs in four migraine susceptible loci in Han Chinese were not risk factors for migraines in a relatively small sample of the She population.
Style APA, Harvard, Vancouver, ISO itp.
9

Cooke, Lara J., i Werner J. Becker. "Migraine Prevalence, Treatment and Impact: The Canadian Women and Migraine Study". Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques 37, nr 5 (wrzesień 2010): 580–87. http://dx.doi.org/10.1017/s0317167100010738.

Pełny tekst źródła
Streszczenie:
Background:The prevalence of migraine headache varies somewhat across geographic regions. The last Canadian population-based study of migraine was in 1994. We report the findings of the Canadian Women and Migraine Survey. In addition to reporting migraine prevalence in Canadian women, the survey identified current consultation and treatment practices of women with migraine, and the psychological burden of migraine.Methods:The survey was conducted with a population-based sample of 1210 women using standard telephone research methods. Headache diagnoses were based on the International Headache Society (IHS) Classification.Results:Calculated prevalence of migraine headache was 26%. Only 51% of women with migraine had consulted a physician about their headaches. Women with migraines rely on over-the-counter medications and non-specific prescription medications. Less than 10% of women with migraine use triptans/dihydroergotamine for primary treatment. Ninety seven percent of women with migraine reported at least one psychosocial impact resulting from migraines.Conclusions:The prevalence of migraine in Canadian women appears static, and is again shown to be slightly higher than that reported in the United States. As in other epidemiologic studies, many women with migraine do not seek medical help for their headaches and perhaps as a result, few are using migraine-specific medications to treat their headaches. The impact of migraine on Canadian women is substantial with almost all women with migraine reporting adverse psychosocial effects of migraines on their lives.
Style APA, Harvard, Vancouver, ISO itp.
10

Rościszewska-Żukowska, Iwona, Sabina Galiniak i Halina Bartosik-Psujek. "Clinical Characteristics of Headache in Multiple Sclerosis Patients: A Cross-Sectional Study". Journal of Clinical Medicine 12, nr 10 (17.05.2023): 3518. http://dx.doi.org/10.3390/jcm12103518.

Pełny tekst źródła
Streszczenie:
Primary headaches are known to be associated with multiple sclerosis (MS), but previous studies concerning this relationship are not conclusive. Nowadays, there are no studies assessing the prevalence of headaches in Polish MS patients. The aim of the study was to assess the prevalence and characterise headaches in MS patients treated with disease-modifying therapies (DMTs). In a cross-sectional study of 419 consecutive RRMS patients, primary headaches were diagnosed according to the International Classification of Headache Disorders (ICHD-3) criteria. Primary headaches were observed in 236 (56%) of RRMS patients, with a higher prevalence in women (ratio of 2:1). The most common was migraine 174 (41%) (migraine with aura 80 (45%), migraine without aura 53 (30%), and probable migraine without aura 41 (23%); less frequent was tension-type headache 62 (14%). Female sex was a risk factor for migraines but not for tension-type headaches (p = 0.002). Migraines mostly started before MS onset (p = 0.023). Migraine with aura was associated with older age, longer disease duration (p = 0.028), and lower SDMT (p = 0.002). Longer DMT time was associated with migraine (p = 0.047), particularly migraine with aura (p = 0.035). Typical for migraine with aura were headaches during clinical isolated syndrome (CIS) (p = 0.001) and relapses (p = 0.025). Age and type of CIS, oligoclonal band presence, family MS history, EDSS, 9HTP, T25FW, and type of DMT did not correlate with headache. Headaches are present in more than half of MS patients treated with DMTs; migraines occur almost three times more frequently than tension-type headaches. Migraines with aura headaches during CIS and relapses are typical. Migraine in MS patients had high severity and typical migraine characteristics. DMTs had no correlation with the presence or type of headache.
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Rozprawy doktorskie na temat "Migraine"

1

Sundholm, James, i n/a. "Analysis of Specific Migraine Candidate Genes Mapping to Human Chromosome 1". Griffith University. School of Health Science, 2003. http://www4.gu.edu.au:8080/adt-root/public/adt-QGU20030829.153348.

Pełny tekst źródła
Streszczenie:
Migraine, comprised of migraine with aura (MA) and migraine without aura (MO), is a painful neurovascular disease, affecting approximately 16% of the general population. It is characterised by a wide variety of symptoms including headache, nausea and vomiting, and photo- and phonophobia. The disorder is complex involving not only multiple genes, but also specific environmental factors, which can induce attacks in genetically predisposed individuals. Hyperhomocysteinaemia is a known risk factor for cerebrovascular, peripheral vascular and coronary heart disease. The Methylenetetrahydrofolate Reductase (MTHFR) enzyme is involved in homocysteine metabolism. Furthermore, it has been reported that a homozygous mutation (677C to T; Ala to Val) in the 5,10-MTHFR gene is associated with an elevation in plasma homocysteine levels (Frosst et al., 1995). This common mutation in the MTHFR gene has recently been associated with migraine with aura in a Japanese cohort (Kowa et al., 2000). The present study was designed to determine the prevalence of the MTHFR C677T mutation in Australian patients with migraine and to determine whether this mutation is associated with the disease in Caucasians. A large case-control study, consisting of 270 patients with migraine (167 with aura and 103 without aura), and 270 normal matched controls was investigated. Genotypic results indicated that the prevalence of the homozygous (T/T) genotype in migraine sufferers (15%) was higher than that of controls (9%) (P = 0.084). Furthermore, the frequency of the mutant (T/T) genotype in individuals with MA (19%) was significantly higher than in controls (9%) (P = 0.006). Interestingly, the risk of MA was ~2.5-fold higher in suffers possessing the homozygous variant (OR = 2.52, CI: 1.42 - 4.47, P = 0.0012). To confirm the MTHFR allelic association with MA, family-based tests were performed in an independent pedigrees group, where only those with MA were considered affected. Results from both the Pedigree Disequilibrium Test (PDT) and Family-Based Association Test (FBAT) analysis revealed slight, although not significant (PDT test, P = 132; and FBAT test, P = 0.390), over-transmission of the mutant allele (T) from parents to affected offspring. However, despite the MTHFR variant having a high heterozygosity (0.48), there were a limited number of informative transmissions for the MTHFR variant in the pedigree group resulting in reduced power for these tests. In conclusion, our results support the trends reported in the Japanese migraine study and suggest that the homozygous 677T gene variant causing mild hyperhomocysteinaemia, is a genetic risk factor for migraine, and indicate that further studies investigating the role of this gene are warranted. Mutations in various ion channel genes are responsible for neurovascular and other neurological disorders. Inherited ion channel mutations or "channelopathies" are increasingly found to be the cause of various neurological disorders in humans. Wittekindt and colleagues (1998) reported that the calcium-activated potassium channel (hKCa3) gene is a good candidate for schizophrenia and bipolar disorder (BD), as well as for other neurological disorders such as migraine. The hKCa3 gene is a neuronal small conductance calcium-activated potassium channel, which contains a polyglutamine tract, encoded by a polymorphic CAG repeat in the gene. The hKCa3 gene encodes a protein of 731 amino acids containing two adjacent polyglutamine sequences in its N-terminal domain separated by 25 amino acids. The C-terminal polyglutamine sequence is highly polymorphic in length (Austin et al., 1999). hKCa3 plays a critical role in determining the firing pattern of neurons via the generation of slow after-polarization pulses and the regulation of intracellular calcium channels (Kohler et al., 1996). Three distinct mutations in the a1 calcium channel gene have been shown to cause SCA-6, episodic ataxia-2 and familial hemiplegic migraine (FHM) (Ophoff et al., 1996). The hKCa3 gene contains a highly polymorphic CAG repeat that was initially mapped (Chandy et al., 1997) to a schizophrenia locus on chromosome 22 (Pulver et al., 1994). Recently Austin et al (1999) re-mapped hKCa3 and found it to reside on chromosome 1q21, a region that has been linked to FHM (Austin et al., 1999), a rare subtype of MA (Ducros et al., 1997; Gardner et al., 1998), and a region recently showing genetic linkage to typical migraine (Lea et al., 2002). The hKCa3 polymorphism results in small variations in polyglutamine number, similar to those that occur in the calcium channel a1a subunit gene (CACNA1A), which is encoded by CAG expansions and thought to cause Spinocerebellar Ataxia Type 6 via loss of channel function (Austin et al., 1999). Given the recent linkage of FHM to the region of chromosome 1q21, to which hKCa3 resides, and also linkage of typical migraine to this region, a large case-control study investigating this hKCa3 CAG marker and consisting of 270 migraine and 270 stringently matched healthy controls was undertaken. Our results indicated that there was no statistically significant difference in allele distributions for this marker between migraine and non-migraine patients (P >0.05). No significant difference in the allelic distribution was observed in the MA or MO groups when compared to controls (P >0.05) and there was no significant difference in CAG repeat length distribution between the migraine group and controls (P = 0.92), or between the MA and MO groups (P = 0.72) collectively. Hence, the CAG repeat in this gene does not show expansion in migraine. Overall, our results provide no genetic evidence to suggest that the hKCa3 CAG repeat polymorphism is involved in migraine aetiology in Australian Caucasians. Thus the involvement of the hKCa3 gene in migraine is not likely, although the hKCa3 gene remains an important candidate for other neurological disorders that may be linked to the 1q21.3 chromosomal region.
Style APA, Harvard, Vancouver, ISO itp.
2

Sundholm, James. "Analysis of Specific Migraine Candidate Genes Mapping to Human Chromosome 1". Thesis, Griffith University, 2003. http://hdl.handle.net/10072/367192.

Pełny tekst źródła
Streszczenie:
Migraine, comprised of migraine with aura (MA) and migraine without aura (MO), is a painful neurovascular disease, affecting approximately 16% of the general population. It is characterised by a wide variety of symptoms including headache, nausea and vomiting, and photo- and phonophobia. The disorder is complex involving not only multiple genes, but also specific environmental factors, which can induce attacks in genetically predisposed individuals. Hyperhomocysteinaemia is a known risk factor for cerebrovascular, peripheral vascular and coronary heart disease. The Methylenetetrahydrofolate Reductase (MTHFR) enzyme is involved in homocysteine metabolism. Furthermore, it has been reported that a homozygous mutation (677C to T; Ala to Val) in the 5,10-MTHFR gene is associated with an elevation in plasma homocysteine levels (Frosst et al., 1995). This common mutation in the MTHFR gene has recently been associated with migraine with aura in a Japanese cohort (Kowa et al., 2000). The present study was designed to determine the prevalence of the MTHFR C677T mutation in Australian patients with migraine and to determine whether this mutation is associated with the disease in Caucasians. A large case-control study, consisting of 270 patients with migraine (167 with aura and 103 without aura), and 270 normal matched controls was investigated. Genotypic results indicated that the prevalence of the homozygous (T/T) genotype in migraine sufferers (15%) was higher than that of controls (9%) (P = 0.084). Furthermore, the frequency of the mutant (T/T) genotype in individuals with MA (19%) was significantly higher than in controls (9%) (P = 0.006). Interestingly, the risk of MA was ~2.5-fold higher in suffers possessing the homozygous variant (OR = 2.52, CI: 1.42 - 4.47, P = 0.0012). To confirm the MTHFR allelic association with MA, family-based tests were performed in an independent pedigrees group, where only those with MA were considered affected. Results from both the Pedigree Disequilibrium Test (PDT) and Family-Based Association Test (FBAT) analysis revealed slight, although not significant (PDT test, P = 132; and FBAT test, P = 0.390), over-transmission of the mutant allele (T) from parents to affected offspring. However, despite the MTHFR variant having a high heterozygosity (0.48), there were a limited number of informative transmissions for the MTHFR variant in the pedigree group resulting in reduced power for these tests. In conclusion, our results support the trends reported in the Japanese migraine study and suggest that the homozygous 677T gene variant causing mild hyperhomocysteinaemia, is a genetic risk factor for migraine, and indicate that further studies investigating the role of this gene are warranted. Mutations in various ion channel genes are responsible for neurovascular and other neurological disorders. Inherited ion channel mutations or "channelopathies" are increasingly found to be the cause of various neurological disorders in humans. Wittekindt and colleagues (1998) reported that the calcium-activated potassium channel (hKCa3) gene is a good candidate for schizophrenia and bipolar disorder (BD), as well as for other neurological disorders such as migraine. The hKCa3 gene is a neuronal small conductance calcium-activated potassium channel, which contains a polyglutamine tract, encoded by a polymorphic CAG repeat in the gene. The hKCa3 gene encodes a protein of 731 amino acids containing two adjacent polyglutamine sequences in its N-terminal domain separated by 25 amino acids. The C-terminal polyglutamine sequence is highly polymorphic in length (Austin et al., 1999). hKCa3 plays a critical role in determining the firing pattern of neurons via the generation of slow after-polarization pulses and the regulation of intracellular calcium channels (Kohler et al., 1996). Three distinct mutations in the a1 calcium channel gene have been shown to cause SCA-6, episodic ataxia-2 and familial hemiplegic migraine (FHM) (Ophoff et al., 1996). The hKCa3 gene contains a highly polymorphic CAG repeat that was initially mapped (Chandy et al., 1997) to a schizophrenia locus on chromosome 22 (Pulver et al., 1994). Recently Austin et al (1999) re-mapped hKCa3 and found it to reside on chromosome 1q21, a region that has been linked to FHM (Austin et al., 1999), a rare subtype of MA (Ducros et al., 1997; Gardner et al., 1998), and a region recently showing genetic linkage to typical migraine (Lea et al., 2002). The hKCa3 polymorphism results in small variations in polyglutamine number, similar to those that occur in the calcium channel a1a subunit gene (CACNA1A), which is encoded by CAG expansions and thought to cause Spinocerebellar Ataxia Type 6 via loss of channel function (Austin et al., 1999). Given the recent linkage of FHM to the region of chromosome 1q21, to which hKCa3 resides, and also linkage of typical migraine to this region, a large case-control study investigating this hKCa3 CAG marker and consisting of 270 migraine and 270 stringently matched healthy controls was undertaken. Our results indicated that there was no statistically significant difference in allele distributions for this marker between migraine and non-migraine patients (P >0.05). No significant difference in the allelic distribution was observed in the MA or MO groups when compared to controls (P >0.05) and there was no significant difference in CAG repeat length distribution between the migraine group and controls (P = 0.92), or between the MA and MO groups (P = 0.72) collectively. Hence, the CAG repeat in this gene does not show expansion in migraine. Overall, our results provide no genetic evidence to suggest that the hKCa3 CAG repeat polymorphism is involved in migraine aetiology in Australian Caucasians. Thus the involvement of the hKCa3 gene in migraine is not likely, although the hKCa3 gene remains an important candidate for other neurological disorders that may be linked to the 1q21.3 chromosomal region.
Thesis (Masters)
Master of Philosophy (MPhil)
School of Health Sciences
Full Text
Style APA, Harvard, Vancouver, ISO itp.
3

Soula, P. Ch Eugène. "Contribution à l'étude de la migraine". Paris : BIUM, 2004. http://www.bium.univ-paris5.fr/histmed/medica/cote?TPAR1884x035.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Tamin, Onésime. "Etude et traitement de l'hémipéricranalgie(migraine) thèse pour le doctorat en médecine présentée et soutenue le 11 juillet 1866 /". Paris : BIUM, 2004. http://www.bium.univ-paris5.fr/histmed/medica/cote?TPAR1860x119.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Aguila, Maria Eliza. "Understanding migraine". Thesis, The University of Sydney, 2017. http://hdl.handle.net/2123/17042.

Pełny tekst źródła
Streszczenie:
Better characterisation of migraine is critical to enhancing its diagnosis, assessment and, ultimately, effective treatments. The aim of this thesis was to better characterise migraine through more detailed investigation of selected headache-related factors and to compare these factors with those seen in other commonly occurring recurrent headaches. The factors investigated in this thesis were neurochemical profile, cervical musculoskeletal impairments, and patient experience, represented by pain and disability characteristics, emotional state and other personal factors. This thesis provides deeper information regarding the nature and characteristics of migraine compared with non-migraine headaches (tension-type and cervicogenic headaches). This thesis has established the potential of GABA as a biomarker for migraine and implies the possible role of GABA in the disease process. This thesis has also characterised migraine according to cervical musculoskeletal impairments and patient experience embodying disability, pain, central sensitisation, and other personal factors. The implications for clinical practice are to assess cervical musculoskeletal impairments and patient experience to facilitate differential diagnosis and prognostication, and to educate patients on the nature of their headaches. Findings from the thesis may also be used by guideline developers, providing stimulus for further discussions on the definition of migraine and reporting of participant selection criteria, with reference to this definition, in clinical trials. Future research directions are identified in validating GABA as a migraine biomarker and elucidating its pathophysiology. By characterising migraine more fully, findings from this thesis will inform the development of effective treatments that could possibly target GABA or clinical characteristics found to be present in migraine. Ultimately this should achieve better health outcomes for people with migraine.
Style APA, Harvard, Vancouver, ISO itp.
6

Molènes, jean Jacques Marc de. "De la migraine thèse pour le doctorat en médecine présentée et soutenue le 25 juillet 1853 /". Paris : BIUM, 2004. http://www.bium.univ-paris5.fr/histmed/medica/cote?TPAR1853x173.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Person, Bertil. "Migrän genetiskt inflytande uppväxtförhållanden och personlighet i migränfamiljen /". Lund : Lunds Universitet, 1994. http://catalog.hathitrust.org/api/volumes/oclc/68945085.html.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Tessier, Cécile Biard Jean-François. "Phytothérapie et migraine". [S.l.] : [s.n.], 2004. http://theses.univ-nantes.fr/thesemed/PHtessier.pdf.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Goëde, Ferdinand. "De la migraine". Paris : BIUM, 2005. http://www.bium.univ-paris5.fr/histmed/medica/cote?TMON1860x005.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Huckins, Jamie L. "Effects of Behavioral Migraine Management Treatment and Preventative Drug Therapy on Positive Psychological and Palliative Migraine Management in Frequent Migraine". Ohio University / OhioLINK, 2009. http://rave.ohiolink.edu/etdc/view?acc_num=ohiou1237408570.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Książki na temat "Migraine"

1

Shah, Shalini, red. Migraine. Cham: Springer International Publishing, 2021. http://dx.doi.org/10.1007/978-3-030-75239-2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Sacks, Oliver W. Migraine. New York: Vintage Books, 1999.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Sacks, Oliver W. Migraine. London: Picador, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Daniel, Britt Talley. Migraine. Bloomington, IN: AuthorHouse, 2010.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Dowson, Andrew J. Migraine. London: Mosby, 2002.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Blau, Joseph N. Migraine. London: Office of Health Economics, 1991.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Sacks, Oliver W. Migraine. Berkeley: University of California Press, 1992.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

South, Valerie. Migraine. Toronto: Key Porter Books, 1994.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Sacks, Oliver W. Migraine. London: Picador, 1995.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Foster, Carol A. Migraine. London: Dorling Kindersley Limited, 2008.

Znajdź pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Więcej źródeł

Części książek na temat "Migraine"

1

Trouw, Michiel. "Is migraine altijd migraine?" W Fysiotherapeutische casuïstiek, 1474–87. Houten: Bohn Stafleu van Loghum, 2006. http://dx.doi.org/10.1007/978-90-313-8645-1_226.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Öztürk, Şerefnur. "Migraine". W Neurological Disorders in Clinical Practice, 33–36. Cham: Springer International Publishing, 2016. http://dx.doi.org/10.1007/978-3-319-23168-6_5.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Gilbert, Patricia. "Migraine". W The A-Z Reference Book of Childhood Conditions, 116–20. Boston, MA: Springer US, 1995. http://dx.doi.org/10.1007/978-1-4899-7098-5_28.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Graff-Radford, Steven B. "Migraine". W Orofacial Disorders, 245–56. Cham: Springer International Publishing, 2017. http://dx.doi.org/10.1007/978-3-319-51508-3_22.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Winkelman, Marc. "Migraine". W Encyclopedia of Women’s Health, 826–28. Boston, MA: Springer US, 2004. http://dx.doi.org/10.1007/978-0-306-48113-0_276.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Merry, Roger. "Migraine". W Teacher Information Pack 4: Physical, 149–56. London: Macmillan Education UK, 1985. http://dx.doi.org/10.1007/978-1-349-09003-7_16.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Filippi, Massimo, i Maria A. Rocca. "Migraine". W White Matter Diseases, 185–208. Cham: Springer International Publishing, 2020. http://dx.doi.org/10.1007/978-3-030-38621-4_8.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Fry, John, Gerald Sandler i David Brooks. "Migraine". W Disease Data Book, 267–79. Dordrecht: Springer Netherlands, 1986. http://dx.doi.org/10.1007/978-94-009-4149-6_16.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Davassi, Chiara, Patrizia Pulitano i Oriano Mecarelli. "Migraine". W Clinical Electroencephalography, 697–705. Cham: Springer International Publishing, 2019. http://dx.doi.org/10.1007/978-3-030-04573-9_43.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

Fry, John, John Trounce i Martin Godfrey. "Migraine". W Commonsense use of Medicines, 105–15. Dordrecht: Springer Netherlands, 1988. http://dx.doi.org/10.1007/978-94-009-1295-3_10.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Streszczenia konferencji na temat "Migraine"

1

Hurrell, Rowan J. W., i Elizabeth A. Streeten. "When a Migraine Is Not a Migraine". W Selection of Abstracts From NCE 2015. American Academy of Pediatrics, 2017. http://dx.doi.org/10.1542/peds.140.1_meetingabstract.50.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
2

Carneiro, Leandro Gouveia, Ana Paula Cuchera i Lucas Andreo. "Epidemiological profile of migraine admissions at the Brazilian Unified Health System (SUS) between 2012 and 2022: a decade of pain." W XIV Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2023. http://dx.doi.org/10.5327/1516-3180.141s1.510.

Pełny tekst źródła
Streszczenie:
Introduction: Migraine is a type of headache characterized by a pulsating pain or sensation, and the pathophysiology is still not fully understood. There are two types of migraines, with aura and without aura, the latter being the most frequent. World Health Organization data suggest that, globally, the estimated prevalence of any type of headache among adults can reach up to 50%, being the sixth highest worldwide cause of years lost due to disability. In Brazil, about 15.8% of the population suffers from migraine. Studies are needed to draw more attention to this disease that causes much morbidity and disabling. Objectives: The aim of this study is to analyze the epidemiology of migraine admissions at the Brazilian Unified Health System (SUS) from 2012 to 2022. Methods: This is a descriptive epidemiological study, in which migraine admissions data was collected using the SUS Hospital Information System database (DATASUS/TABNET), from 2012 to 2022, by region, using the term “Enxaqueca e outras síndromes de algias cefálicos”. Literature review was conducted using PubMed and SciELO databases. Statistical analysis was performed with Kolmogorov-Smirnov and analysis of variance/Tukey tests, using the PRISM software. Results: From 2012 and 2022, Brazil had 96,857 migraine admissions. The most prevalent region is the southeast of Brazil with 33,487 admissions (P < 0.05 when compared to north and midwest). The least prevalent region is the midwest, totalling 5,026 admissions. The year with most recorded migraines were 2019, with a total of 11,996 admissions, and 2012 the least prevalent, with 5,908 admissions. Of all admissions, 65% occurred in women, being the most prevalent age group from 30 to 39 years old. Conclusion: We observed an increase in hospital admissions by migraines in the last decade, particularly between women and in the southeast region of Brazil.
Style APA, Harvard, Vancouver, ISO itp.
3

Pereira, Camila Nakamura Perissê, Lamys Fernandes Kozak, Victor Fernandes Feitosa Braga, Pedro Henrique Bersan de Menezes i Alexandre Sampaio Rodrigues Pereira. "The use of erenumab for preventing migraine". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.191.

Pełny tekst źródła
Streszczenie:
Background: In 2018, calcitonin gene-related peptides (CGRP) were approved in the United States as the first class of specific migraine prevention drugs. Objectives: To analyze the efficacy and therapeutic safety of erenumab for preventing migraine. Methods: A narrative literature review was carried out by researching in the PubMed/MEDLINE and SciELO databases, using the descriptor “migraine disorders” and the keyword “erenumab” combined by the Boolean operator AND. Eight articles were selected, between 2017 and 2020. Results: The pathophysiology of migraine is related to CGRP through nociceptive modulation in the trigeminovascular system. Therefore, erenumab was developed, which is a human monoclonal antibody that binds selectively and potently to the canonical receptor of CGRP and acts as an antagonist of CGRP. Evidence indicates that the monthly dose of 70mg or 140mg reduces the frequency, quality and intensity of acute and chronic migraines. Studies report a decrease of two to six days of migraine using erenumab. The same adverse reactions occurred in both placebo and experimental groups, including upper respiratory tract viral infection, pain at the injection site and nausea. Conclusions: Erenumab is a promising drug, because it showed efficacy in the first days of treatment, absence of significant side effects and low rate of discontinuation. Aspects such as safety, effect durability, impact on quality of life and cost require further research.
Style APA, Harvard, Vancouver, ISO itp.
4

Ceddaha Zibi, A. "Migraine faciale à expression dentaire, à propos de trois cas". W 66ème Congrès de la SFCO. Les Ulis, France: EDP Sciences, 2020. http://dx.doi.org/10.1051/sfco/20206603016.

Pełny tekst źródła
Streszczenie:
Migraine faciale à expression dentaire, à propos de trois cas. Anael CEDDAHA ZIBI1, Vanina LUCIANI2, Diane NGUYEN3, Audrey CHANLON3, Nathan MOREAU4,5 1 - Interne en chirurgie orale 2 - Etudiante en 6ème année de chirurgie dentaire, Faculté de Chirurgie dentaire, Université Paris Descartes 3 - Praticien attaché, consultation de diagnostic et traitement des douleurs chroniques oro-faciales, service de médecine bucco-dentaire, Hôpital Bretonneau, AP-HP, Paris 4 - Responsable de la consultation de diagnostic et traitement des douleurs chroniques oro-faciales, service de médecine bucco-dentaire, Hôpital Bretonneau, AP-HP, Paris 5 - MCU-PH en médecine et chirurgie orale, Faculté de Chirurgie Dentaire, Université Paris Descartes & Service de Médecine buccodentaire, Hôpital Bretonneau, AP-HP, Paris & Laboratoire de Neurobiologie Oro-Faciale, Université Paris Diderot La migraine est une affection neurovasculaire qui peut être invalidante, sa pathogénie n’est pas encore parfaitement élucidée aujourd’hui. Le plus souvent à type de céphalée, elle représente la céphalée primaire la plus fréquente. Si son diagnostic est aisé lorsqu’elle se présente sous forme de céphalée, il devient plus délicat devant des manifestations faciales de migraines moins typiques. Les migraines avec une atteinte oro-faciale stricte sont peu décrites dans la littérature. Notre étude portera sur trois cas de patients recrutés et suivis à la consultation douleur de l’hôpital Bretonneau ayant souffert de douleurs oro- faciales, étiquetées comme migraines. Ce diagnostic ayant été confirmé par la suite lors de leurs prise en charge en neurologie. Dans le cas des migraines à expression dentaire, la maladie si elle est méconnue risque d’entraîner des traitements dentaires abusifs et inadaptés, comme cela a été le cas pour ces trois patientes. L’errance diagnostique et la chronicité des douleurs engendrent une dégradation de la qualité de vie des malades, et impacte souvent leur relation affective et professionnelle. L’aspect économique des traitements dentaires à répétition chez ces patients n’est pas à négliger. Si la migraine est une maladie bénigne elle peut devenir invalidante. La forte prévalence des migraines dans la population générale et dans la population active en fait une des priorités de santé publique du fait de son retentissement économique. Les objectifs de la prise en charge thérapeutique prennent en compte l’éradication des facteurs déclenchant des crises, le traitement de la crise migraineuse, et un traitement de fond prophylactique lorsque la fréquence des crises est importante. La migraine demeure une maladie sous-diagnostiquée dans toutes ses formes d’expression. Un diagnostic précoce demeure pourtant indispensable pour une prise en charge optimale en particulier en cas de manifestations oro-faciales pures.
Style APA, Harvard, Vancouver, ISO itp.
5

Soares, Samantha Lia Ziotti Bohn Gonçalves, Letícia Santana Ferreira Gonçalves, Emily Thauara de Souza, Pollyana Yuri Salles Suguinoshita, Luana Isla Rocha Alves, Anna Mariah R. ibeiro Oliveira, Thalia Castro Souza i Bárbara Machado Garcia. "Clinical correlation between Migraine and Generalized Anxiety Disorders: a literature review". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.154.

Pełny tekst źródła
Streszczenie:
Background: Migraine and anxiety are common neuro-psychiatric disorders in clinical practice, sharing symptoms and epidemiological factors among themselves. The presence of both pathologies in the same individual is frequently reported in the literature. Objectives: To report the clinical and epidemiological correlations established between generalized anxiety disorder and migraine. Methodology: Systematic review of studies published between 2016 and 2021, exploring the association between generalized anxiety disorders and Migraine. The descriptors “association”, “Migraines” and “Generalized Anxiety Disorder” were used in the LILACS, SCIELO and PUBMED databases. Fourteen articles were selected, mostly dealing with epidemiological studies. Results: Evidence suggests that these pathologies are associated and share common symptoms, pathophysiology and epidemiological factors. Studies corroborate that anxiety and painful sensation are more strongly associated with migraine than with other psychiatric illnesses. It has also demonstrated some characteristics of patients who are predisposed to develop both comorbidities such as smoke, low income and a history of other previous diseases. Common triggering factors such as pain, sleep disorders and stress can also contribute to the association between pathologies. Conclusions: Based on the studies analyzed in full, the high prevalence of both diseases in the same individual highlights the importance of research on the cause and consequence relationship between Anxiety and Migraine, since this is not yet clarified in the medical literature. In addition, paying attention to migraine correlation to generalized anxiety disorder increases the quality of life of the patient in the short and long term, as well as help in the choice of better treatments.
Style APA, Harvard, Vancouver, ISO itp.
6

Paroz, Andrew, i Leigh Ellen Potter. "Cybersickness and migraine triggers". W OzCHI '17: 29th Australian Conference on Human-Computer Interaction. New York, NY, USA: ACM, 2017. http://dx.doi.org/10.1145/3152771.3156148.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
7

Akin, Ata, Uzay E. Emir, Didem Bilensoy, Gulin Erdogan, Selcuk Candansyar i Hayrunnisa Bolay. "fNIRS measurements in migraine". W Biomedical Optics 2005, redaktorzy Britton Chance, Robert R. Alfano, Bruce J. Tromberg, Mamoru Tamura i Eva M. Sevick-Muraca. SPIE, 2005. http://dx.doi.org/10.1117/12.590594.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Godk, Keryn Sporh, Maria Luiza dos Santos, Elcio Juliato Piovesan, Marco Antônio Takashi Utiumi, João Guilherme Bochnia Küster, Luiz Carlos Canalli Filho, Nikolai José Eustátios Kotsifas, Bin Cheng Tan, Eldislei Mioto i Gabriel Eduardo Faria Colombani. "Association of sleep and wake bruxism in patients with migraine". W XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.180.

Pełny tekst źródła
Streszczenie:
Introduction: When migraine evolves from episodic to chronic form, it becomes more disabling, due to refractory treatment and the arising of comorbidities. Bruxism has already been associated with migraine in adults, with a bidirectional relationship between sleep bruxism and chronic migraine. This study aimed to assess whether sleep and wake bruxism are more prevalent in chronic migraine when compared to episodic migraine and also to establish possible clinical correlations with chronification. Methods: 210 patients were allocated to the study, 97 with episodic migraine (EM) and 113 with chronic migraine (CM). The patients were submitted to face-to-face interviews with a neurologist to confirm the diagnosis and fill in the scales: specific questionnaire for the diagnosis of sleep and wake bruxism, PHQ-9 (depression), GAD-7 (anxiety), Epworth Scale (sleepness), MIDAS and HIT-6 scales to assess the migraine disability and the headache impact on patients. Results: The prevalence of sleep and wake bruxism was similar in patients with EM versus CM (p=0.300 and p=0.238). The correlation of patients with both bruxism forms at the same time with the high scores on the migraine disability and the headache impact, was higher among patients with chronic migraine than in patients with chronic migraine. episodic migraine (p <0.001). Conclusion: Sleep and wake bruxism alone aren’t more prevalent in chronic migraine when compared to episodic migraine. In patients affected with both bruxism forms, bruxism only causes a greater impact and disability on individuals with chronic migraine.
Style APA, Harvard, Vancouver, ISO itp.
9

Crunkhorn, Rosa, Sudhira Ratnayake i Soumit Dasgupta. "1747 Vestibular Migraine in Children". W Royal College of Paediatrics and Child Health, Abstracts of the RCPCH Conference–Online, 15 June 2021–17 June 2021. BMJ Publishing Group Ltd and Royal College of Paediatrics and Child Health, 2021. http://dx.doi.org/10.1136/archdischild-2021-rcpch.826.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
10

"Advanced Migraine Prediction Hardware System". W 2018 Summer Simulation Multi-Conference. Society for Modeling and Simulation International (SCS), 2018. http://dx.doi.org/10.22360/summersim.2018.scsc.011.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.

Raporty organizacyjne na temat "Migraine"

1

Halker Singh, Rashmi B., Juliana H. VanderPluym, Allison S. Morrow, Meritxell Urtecho, Tarek Nayfeh, Victor D. Torres Roldan, Magdoleen H. Farah i in. Acute Treatments for Episodic Migraine. Agency for Healthcare Research and Quality (AHRQ), grudzień 2020. http://dx.doi.org/10.23970/ahrqepccer239.

Pełny tekst źródła
Streszczenie:
Objectives. To evaluate the effectiveness and comparative effectiveness of pharmacologic and nonpharmacologic therapies for the acute treatment of episodic migraine in adults. Data sources. MEDLINE®, Embase®, Cochrane Central Registrar of Controlled Trials, Cochrane Database of Systematic Reviews, PsycINFO®, Scopus, and various grey literature sources from database inception to July 24, 2020. Comparative effectiveness evidence about triptans and nonsteroidal anti-inflammatory drugs (NSAIDs) was extracted from existing systematic reviews. Review methods. We included randomized controlled trials (RCTs) and comparative observational studies that enrolled adults who received an intervention to acutely treat episodic migraine. Pairs of independent reviewers selected and appraised studies. Results. Data on triptans were derived from 186 RCTs summarized in nine systematic reviews (101,276 patients; most studied was sumatriptan, followed by zolmitriptan, eletriptan, naratriptan, almotriptan, rizatriptan, and frovatriptan). Compared with placebo, triptans resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (high strength of the body of evidence [SOE]). Data on NSAIDs were derived from five systematic reviews (13,214 patients; most studied was ibuprofen, followed by diclofenac and ketorolac). Compared with placebo, NSAIDs probably resolved pain at 2 hours and 1 day, and increased the risk of mild and transient adverse events (moderate SOE). For other interventions, we included 135 RCTs and 6 comparative observational studies (37,653 patients). Compared with placebo, antiemetics (low SOE), dihydroergotamine (moderate to high SOE), ergotamine plus caffeine (moderate SOE), and acetaminophen (moderate SOE) reduced acute pain. Opioids were evaluated in 15 studies (2,208 patients).Butorphanol, meperidine, morphine, hydromorphone, and tramadol in combination with acetaminophen may reduce pain at 2 hours and 1 day, compared with placebo (low SOE). Some opioids may be less effective than some antiemetics or dexamethasone (low SOE). No studies evaluated instruments for predicting risk of opioid misuse, opioid use disorder, or overdose, or evaluated risk mitigation strategies to be used when prescribing opioids for the acute treatment of episodic migraine. Calcitonin gene-related peptide (CGRP) receptor antagonists improved headache relief at 2 hours and increased the likelihood of being headache-free at 2 hours, at 1 day, and at 1 week (low to high SOE). Lasmiditan (the first approved 5-HT1F receptor agonist) restored function at 2 hours and resolved pain at 2 hours, 1 day, and 1 week (moderate to high SOE). Sparse and low SOE suggested possible effectiveness of dexamethasone, dipyrone, magnesium sulfate, and octreotide. Compared with placebo, several nonpharmacologic treatments may improve various measures of pain, including remote electrical neuromodulation (moderate SOE), magnetic stimulation (low SOE), acupuncture (low SOE), chamomile oil (low SOE), external trigeminal nerve stimulation (low SOE), and eye movement desensitization re-processing (low SOE). However, these interventions, including the noninvasive neuromodulation devices, have been evaluated only by single or very few trials. Conclusions. A number of acute treatments for episodic migraine exist with varying degrees of evidence for effectiveness and harms. Use of triptans, NSAIDs, antiemetics, dihydroergotamine, CGRP antagonists, and lasmiditan is associated with improved pain and function. The evidence base for many other interventions for acute treatment, including opioids, remains limited.
Style APA, Harvard, Vancouver, ISO itp.
2

White, Hunter. Literature Review in Typical Migraine. Ames (Iowa): Iowa State University, styczeń 2019. http://dx.doi.org/10.31274/cc-20240624-961.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
3

Charles, Andrew. Novel Therapeutic Targets for Chronic Migraine. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2013. http://dx.doi.org/10.21236/ada612867.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
4

Charles, Andrew, i Peter Goadsby. Novel Therapeutic Targets for Chronic Migraine. Fort Belvoir, VA: Defense Technical Information Center, wrzesień 2012. http://dx.doi.org/10.21236/ada566633.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
5

Charles, Andrew, i Peter Goadsby. Novel Therapeutic Targets for Chronic Migraine. Fort Belvoir, VA: Defense Technical Information Center, listopad 2014. http://dx.doi.org/10.21236/ada623382.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
6

Research, Gratis. Green Light: A New Preventive Therapy for Migraine. Gratis Research, listopad 2020. http://dx.doi.org/10.47496/gr.blog.03.

Pełny tekst źródła
Streszczenie:
Manipulating the ability of green light to create the least amount of electrical signals in retina and brain cortex, green light therapy offers an excellent therapeutic role in reducing migraine pain and improves the quality of life
Style APA, Harvard, Vancouver, ISO itp.
7

VanderPluym, Juliana H., Rashmi B. Halker Singh, Magdoleen H. Farah, Kelly E. Viola, Bashar Hasan, Samer Saadi, Sahrish Shah i in. Acute Treatments for Episodic Migraine: Surveillance Report 3. Agency for Healthcare Research and Quality (AHRQ), sierpień 2022. http://dx.doi.org/10.23970/ahrqepcmigrainesurveillance3.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
8

Pluym, Juliana H. Vande, Rashmi B. Halker Singh, Magdoleen H. Farah, Kelly E. Viola, Bashar Hasan, Samer Saadi, Sahrish Shah i in. Acute Treatments for Episodic Migraine: Surveillance Report 2. Agency for Healthcare Research and Quality (AHRQ), kwiecień 2022. http://dx.doi.org/10.23970/ahrqepcmigrainesurveillance2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
9

Li, Xiao, GX Xu, FY Ling, ZH Yin, Y. Wei,, Y. Zhao, Xn Li, WC Qi, L. Zhao i FR Liang. The dose-effect association between electroacupuncture sessions and its effect on chronic migraine: a protocol of a meta-regression of randomized controlled trials. INPLASY - International Platform of Registered Systematic Review and Meta-analysis Protocols, grudzień 2022. http://dx.doi.org/10.37766/inplasy2022.12.0085.

Pełny tekst źródła
Streszczenie:
Review question / Objective: We will use a meta-regression approach to verify the dose-effect relationship between the number of electroacupuncture sessions and its effects on migraine. Condition being studied: Migraine is recurrent and chronic, requiring long-term control, but the side effects caused by long-term use limit the use of pharmacotherapy, like non-steroidal anti-inflammatory drugs (NSAIDS), ergoamines and opioids. With fewer side effects and lower cost, acupuncture is becoming a more attractive option for migraine. Relevant studies have confirmed the clinical effects of electroacupuncture on migraine and its effects on intracranial blood flow velocity, functional brain imaging and neuroinflammation. However, uncertainty exists regarding the dose-effect between electroacupuncture and migraine. In recent years, inspired by the dose-effect researches in pharmacology and epidemiology, researches focusing on the dose-effect association between acupuncture and diseases has also begun to emerge. So in this protocol, we designed to use a meta-regression approach to explore the optimal electroacupuncture dose for migraine.
Style APA, Harvard, Vancouver, ISO itp.
10

Tsou, Amy, Benjamin Rouse, Aaron Bloschichak i Jonathan Treadwell. Drugs and Devices for Migraine Prevention: Interactive Evidence Maps. Patient-Centered Outcomes Research Institute (PCORI), luty 2021. http://dx.doi.org/10.25302/emv1.2021.2.

Pełny tekst źródła
Style APA, Harvard, Vancouver, ISO itp.
Możesz być także zainteresowany rozszerzonymi bibliografiami na temat „Migraine” dla poszczególnych typów źródeł:
Artykuły w czasopismach Rozprawy doktorskie Książki
Oferujemy zniżki na wszystkie plany premium dla autorów, których prace zostały uwzględnione w tematycznych zestawieniach literatury. Skontaktuj się z nami, aby uzyskać unikalny kod promocyjny!

Do bibliografii